ArticleCancer discovery2021
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.Blood · 2026Article
- ZEB1 drives terminal erythroid maturation by controlling the GATA2-KLF1 regulatory switch.Nucleic acids research · 2026Article
- Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia.Oncogene · 2026Article
- BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.Leukemia · 2026Article
- Mechanisms of enhancer-driven oncogene activation.International journal of cancer · 2026Review
- Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.HemaSphere · 2026Article
- The oncogenic role of ecotropic viral integration site 1 in hematological malignancies: mechanisms of activation and leukemogenesis.Frontiers in immunology · 2026Review
- BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia.Scientific reports · 2025Article
- Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance.Nature communications · 2025Article
- Oncogenic Enhancers in Leukemia.Blood cancer discovery · 2024Review
- The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.HemaSphere · 2024Article
- OncogeneScience advances · 2024Article
- Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.Leukemia · 2024Article
- BloodChIP Xtra: an expanded database of comparative genome-wide transcription factor binding and gene-expression profiles in healthy human stem/progenitor subsets and leukemic cells.Nucleic acids research · 2024Article
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- Article
- From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis.HemaSphere · 2023Review
- Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer.Cancer immunology, immunotherapy : CII · 2023Article
- A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins.Blood advances · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Leonie SmeenkDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0001-7025-8515
Sophie OttemaDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Roger Mulet-LazaroDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0003-0298-7948
Anja EbertResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0002-2425-473X
Marije HavermansDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Andrea Arricibita VareaDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Michaela FellnerResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Dorien PastoorsDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0002-5322-1961
Stanley van HerkDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0002-8707-703X
Claudia Erpelinck-VerschuerenDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Tim GrobDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Remco M HoogenboezemDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
François G KavelaarsDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Daniel R MatsonDepartment of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-1430-3128
Emery H BresnickDepartment of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0001-9502-669X
Eric M BindelsDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0001-9502-669X
Alex KentsisTow Center for Developmental Oncology, Sloan Kettering Institute, Department of Pediatrics, Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8063-9191
Johannes Zuber *Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Ruud Delwel *Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. h.delwel@erasmusmc.nl.
Utrecht University · NLErasmus MC Cancer Institute · NLResearch Institute of Molecular Pathology · ATUniversity of Wisconsin System · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6MRESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2MHematopoietic Regulation via GATA SwitchesR01DK068634 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI Emery H. Bresnick · 2006 to 2026
$7.5MABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIAR01CA204396 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2016 to 2025
$5.2MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA204396NHLBI NIH HHS T32 HL007899NIDDK NIH HHS R01 DK068634
Abstract
In acute myeloid leukemia (AML) with inv(3)(q21;q26) or t(3;3)(q21;q26), a translocated
Indexed as
Enhancer Elements, GeneticGenes, mybLeukemia, Myeloid, AcuteTranslocation, GeneticGATA2 Transcription FactorHumansMDS1 and EVI1 Complex Locus ProteinOncogenesGATA2 protein, humanGATA2 Transcription FactorMDS1 and EVI1 Complex Locus ProteinMECOM protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.